Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Chronologic Change in the Size and Contrast-Enhancement of Ablation Zones on CT Images after Irreversible Electroporation and Radiofrequency Ablation

  • Scheck, Jonas (Department of Diagnostic and Interventional Radiology, Aachen University Hospital, RWTH Aachen University) ;
  • Bruners, Philipp (Department of Diagnostic and Interventional Radiology, Aachen University Hospital, RWTH Aachen University) ;
  • Schindler, David (Institute of Medical Statistics, Aachen University Hospital, RWTH Aachen University) ;
  • Kuhl, Christiane (Department of Diagnostic and Interventional Radiology, Aachen University Hospital, RWTH Aachen University) ;
  • Isfort, Peter (Department of Diagnostic and Interventional Radiology, Aachen University Hospital, RWTH Aachen University)
  • Received : 2017.06.03
  • Accepted : 2017.12.18
  • Published : 2018.08.01
⟨ Previous Next ⟩

Abstract

Objective: To compare short-, mid-, and long-term follow-up ablation zone volume alterations as well as imaging features on contrast-enhanced computed tomography (CT) after irreversible electroporation (IRE) of primary and secondary liver tumors with findings subsequent to radiofrequency ablation (RFA). Materials and Methods: Volume assessment of 39 ablation zones (19 RFA, 20 IRE) after intervention was performed at four time intervals (day 0 [t1; n = 39], day 1-7 [t2; n = 25], day 8-55 [t3; n = 28], after day 55 [t4; n = 23]) on dual-phase CT. Analysis of peripheral rim enhancement was conducted. Lesion's volume decrease relative to the volume at t1 was calculated and statistically analyzed with respect to patient's sex, age, ablation modality (IRE/RFA), and history of platinum-based chemotherapy (PCT). Results: No influence of patient's sex or age on ablation volume was detected. The decrease in ablation zones' volume was significantly larger (p < 0.05 for all time intervals) after IRE (arterial phase, 7.5%; venous phase, 9.7% of initial volume) compared to RFA (arterial phase, 39.6%; venous phase, 45.3% of initial volume). After RFA, significantly smaller decreases in the ablation volumes, in general, were detected in patients treated with PCT in their history (p = 0.004), which was not detected after IRE (p = 0.288). In the arterial phase, peripheral rim enhancement was frequently detected after both IRE and RFA. In the venous phase, rim-enhancement was depicted significantly more often following IRE at t1 and t2 (pt1 = 0.003, pt2 < 0.001). Conclusion: As per our analysis, ablation zone volume decreased significantly in a more rapid and more profound manner after IRE. Lesion's remodeling after RFA but not IRE seems to be influenced by PCT, possibly due to the type of cell death induced by the different ablation modalities.

Keywords

References

  1. Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005;33:223-231 https://doi.org/10.1007/s10439-005-8981-8
  2. Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology 2010;255:426-433 https://doi.org/10.1148/radiol.10090337
  3. Maor E, Ivorra A, Leor J, Rubinsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007;6:307-312 https://doi.org/10.1177/153303460700600407
  4. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality--clinical implications. Technol Cancer Res Treat 2007;6:37-48 https://doi.org/10.1177/153303460700600106
  5. Chung DJ, Sung K, Osuagwu FC, Wu HH, Lassman C, Lu DS. Contrast enhancement patterns after irreversible electroporation: experimental study of CT perfusion correlated to histopathology in normal porcine liver. J Vasc Interv Radiol 2016;27:104-111 https://doi.org/10.1016/j.jvir.2015.09.005
  6. Dollinger M, Jung EM, Beyer L, Niessen C, Scheer F, Muller-Wille R, et al. Irreversible electroporation ablation of malignant hepatic tumors: subacute and follow-up CT appearance of ablation zones. J Vasc Interv Radiol 2014;25:1589-1594 https://doi.org/10.1016/j.jvir.2014.06.026
  7. Li S, Zeng Q, Zhong R, Mao S, Shen L, Wu P. [Liver regeneration after radiofrequency ablation versus irreversible electroporation]. Zhonghua Yi Xue Za Zhi 2015;95:66-68
  8. Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012;30:1323-1341 https://doi.org/10.1016/j.mri.2012.05.001
  9. Cheng RG, Bhattacharya R, Yeh MM, Padia SA. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis. J Vasc Interv Radiol 2015;26:1184-1188 https://doi.org/10.1016/j.jvir.2015.05.014
  10. Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12:233-241 https://doi.org/10.7785/tcrt.2012.500317
  11. Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 2014;25:997-1011; quiz 1011 https://doi.org/10.1016/j.jvir.2014.01.028
  12. Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 2011;22:611-621 https://doi.org/10.1016/j.jvir.2010.12.014
  13. Niessen C, Jung EM, Wohlgemuth WA, Trabold B, Haimerl M, Schreyer A, et al. Irreversible electroporation of a hepatocellular carcinoma lesion adjacent to a transjugular intrahepatic portosystemic shunt stent graft. Korean J Radiol 2013;14:797-800 https://doi.org/10.3348/kjr.2013.14.5.797
  14. Lee YJ, Lu DS, Osuagwu F, Lassman C. Irreversible electroporation in porcine liver: acute computed tomography appearance of ablation zone with histopathologic correlation. J Comput Assist Tomogr 2013;37:154-158 https://doi.org/10.1097/RCT.0b013e31827dbf9b
  15. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. AJR Am J Roentgenol 2002;179:93-101 https://doi.org/10.2214/ajr.179.1.1790093
  16. Keil S, Bruners P, Schiffl K, Sedlmair M, Muhlenbruch G, Gunther RW, et al. Radiofrequency ablation of liver metastases-software-assisted evaluation of the ablation zone in MDCT: tumor-free follow-up versus local recurrent disease. Cardiovasc Intervent Radiol 2010;33:297-306 https://doi.org/10.1007/s00270-009-9681-9
  17. Lim HK, Choi D, Lee WJ, Kim SH, Lee SJ, Jang HJ, et al. Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001;221:447-454 https://doi.org/10.1148/radiol.2212010446
  18. Siperstein A, Garland A, Engle K, Rogers S, Berber E, Foroutani A, et al. Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7:106-113 https://doi.org/10.1007/s10434-000-0106-x
  19. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88:2452-2463 https://doi.org/10.1002/1097-0142(20000601)88:11<2452::AID-CNCR5>3.0.CO;2-3
  20. Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology 2002;35:1467-1475 https://doi.org/10.1053/jhep.2002.33635
  21. Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, et al. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21-27
  22. Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics 2008;28:379-390; discussion 390-392 https://doi.org/10.1148/rg.282075038
  23. Kim SD, Yoon SG, Sung GT. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol 2012;13:625-633 https://doi.org/10.3348/kjr.2012.13.5.625
  24. Kim HB, Sung CK, Baik KY, Moon KW, Kim HS, Yi JH, et al. Changes of apoptosis in tumor tissues with time after irreversible electroporation. Biochem Biophys Res Commun 2013;435:651-656 https://doi.org/10.1016/j.bbrc.2013.05.039
  25. Golberg A, Bruinsma BG, Jaramillo M, Yarmush ML, Uygun BE. Rat liver regeneration following ablation with irreversible electroporation. PeerJ 2016;4:e1571 https://doi.org/10.7717/peerj.1571
  26. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008;28:337-344 https://doi.org/10.1002/jat.1284
  27. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008;9:231-241 https://doi.org/10.1038/nrm2312
  28. Kim YS, Rhim H, Lim HK, Choi D, Lee MW, Park MJ. Coagulation necrosis induced by radiofrequency ablation in the liver: histopathologic and radiologic review of usual to extremely rare changes. Radiographics 2011;31:377-390 https://doi.org/10.1148/rg.312105056

Cited by

  1. Relationship of Antenna Work and Ablation Cavity Volume Following Percutaneous Microwave Ablation of Hepatic Tumors vol.32, pp.4, 2021, https://doi.org/10.1016/j.jvir.2020.12.012
  2. Imaging after percutaneous thermal and non-thermal ablation of hepatic tumour: normal appearances, progression and complications vol.94, pp.1123, 2018, https://doi.org/10.1259/bjr.20201327